Recent Finacing
Recent Raise
AnTolRx develops antigen-specific Targeted Nanoparticle Tolerance Therapeutics (TNTT) to induce immune tolerance for autoimmune disorders, including type 1 diabetes, based on Dr. Francisco Quintana’s work.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors